Actemra
Biogen’s biosimilar Tofidence approved by FDA
October 2, 2023Medical Communications Actemra, Biogen, FDA, Musculo-skeletal disorder, Tofidence
Biogen has announced that the US Food and Drug Administration (FDA) has approved Tofidence (tocilizumab-bavi) as an intravenous formulation, a …
FDA approves Roche’s Actemra/RoActemra treatment for rare lung disease
March 5, 2021Medical Communications Actemra, RoActemra, Roche, SEC, systemic sclerosis
Roche’s Actemra/RoActemra therapy, intended for slowing the rate of decline in pulmonary function for adults with systemic sclerosis-associated interstitial lung …
Roche’s Actemra fails to improve clinical status in COVID-19-associated pneumonia
July 29, 2020Research and Development Actemra, COVID-19, Roche, pharma
Roche has announced the disappointing news that its therapy Actemra/RoActemra (tocilizumab) failed to improve clinical status to a statistically significant …
Roche’s rheumatoid arthritis drug Actemra shows no benefit in COVID-19 pneumonia
June 18, 2020Research and Development Actemra, COVID-19, Roche, coronavirus
Hope is waning around the efficacy of Roche’s Actemra (tocilizumab) following the release of results from an Italian study focusing …
China approves Roche’s Actemra to fight severe complications stemming from coronavirus
March 5, 2020Sales and Marketing Actemra, China, Roche, coronavirus, pharma
China has moved to authorise Roche’s Actemra (tocilizumab) as a treatment for severe complications from contracting the COVID-19 coronavirus in …
Sanofi & Regeneron’s arthritis drug scores first approval following FDA rejection
February 1, 2017Research and Development, Sales and Marketing Actemra, Humira, Kevzara, Regeneron, Roche, Sanofi, sarilumab
Kevzara (sarilumab), a interleukin-6 (IL06) receptor antibody developed by Sanofi and Regeneron and the first real competitor to Roche’s Actemra …
Roche’s Actemra granted Priority Review by FDA
January 24, 2017Manufacturing and Production, Sales and Marketing Actemra, FDA, Roche, priority review
Roche’s drug, Actemra (also known as RoActemra in Europe), has been granted priority review designation by the FDA for the …
Roche granted breakthrough therapy designation by FDA
October 5, 2016Research and Development Actemra, FDA, Giant Cell arteritis, Roche, breakthrough therapy
Roche has announced that the FDA has granted its Actembra drug breakthrough therapy designation for giant cell arteritis. The breakthrough …
Ablynx’s RA therapy matches Roche’s Actemra in Phase IIb trial
July 7, 2016Medical Communications, Research and Development Ablynx, Actemra, Roche
Ablynx (EBR: ABLX) has presented positive data on their rheumatoid arthritis treatment candidate, ALX-0061 (vobarilizumab), in patients with rheumatoid arthritis …
Oncology drives Roche profits
January 30, 2014Sales and Marketing Actemra, Perjeta, Roche, Swiss, q4
Sales at Roche’s pharma division rose 7% year-on-year in 2013, driven largely by strong performances from its oncology portfolio. Group …
FDA approves Roche’s Actemra
January 11, 2010Sales and Marketing Actemra, RoActemra, Roche, US, rheumatoid arthritis
Roche’s Actemra has been approved in the US for the treatment of moderately to severely active rheumatoid arthritis (RA) and …
